AM-2233 Stats & Data

Potency: AM‑2233 is a highly potent aminoalkylindole full agonist at CB1/CB2; thus very small measurement errors can produce overdose-level exposure. Use precision weighing or volumetric dosing only. Synthetic cannabinoids as a class have a history of severe poisonings and deaths; presentations commonly include agitation, tachycardia, hypertension, seizures, acute kidney injury, rhabdomyolysis, stroke, psychosis, and prolonged vomiting. Adverse event risk is increased by uneven distribution ('hot spots') when a powder is applied to plant material and by variable batch composition. Mixing with other CNS depressants (alcohol, opioids, benzodiazepines) increases risk for profound sedation, emesis/aspiration, and accidents; avoid. Combining with stimulants can markedly increase heart rate/blood pressure and panic; if used at all, space doses and keep stimulant doses low. Tinnitus/ear-pressure phenomena have been specifically reported by users with AM‑2233. Dependence/withdrawal (irritability, insomnia, sweats, cravings) is described after short daily runs; plan breaks of several weeks. Mis-sold/adulterated products are common (e.g., herbal cannabis sprayed with SCRAs); start with a microdose from a new batch, do not chase effects with rapid redosing, and do not drive or operate machinery until fully back to baseline. For oral use, take with dietary fat to improve predictability.